Journal of Andrology, Vol 18, Issue 5 495-500, Copyright © 1997 by The American Society of Andrology

JOURNAL ARTICLE

Serum androgens: associations with prostate cancer risk and hair patterning

W. Demark-Wahnefried, S. M. Lesko, M. R. Conaway, C. N. Robertson, R. V. Clark, B. Lobaugh, B. J. Mathias, T. S. Strigo and D. F. Paulson
Division of Urology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Cancer of the prostate is the leading cancer among American men, yet few risk factors have been established. Hair growth and development are influenced by androgens, and it has long been suspected that prostate cancer also is responsive to these hormones. A blinded, case-control study was undertaken to determine if hair patterning is associated with risk of prostate cancer, as well as specific hormonal profiles. The study accrued 315 male subjects who were stratified with regard to age, race, and case-control status (159 prostate cancer cases/156 controls). Hair-patterning classification and serum levels of total and free testosterone (T), sex hormone binding globulin, and dihydrotestosterone (DHT) were performed. Data indicate that hair patterning did not differ between prostate cancer cases and controls; however, significant hormonal differences were detected between the two groups. Free T was greater among cases than in controls (16.4 +/- 6.1 vs. 14.9 +/- 4.8 pg/ml, P = 0.02). Conversely, DHT-related ratios were greater among controls (P = 0.03 for DHT/T and P = 0.01 for DHT/free T). Several strong associations also were found between hormone levels and hair patterning. Men with vertex and frontal baldness had higher levels of free T (16.5 +/- 5.5 and 16.2 +/- 8.0 pg/ml, respectively) when compared to men with either little or no hair loss (14.8 +/- 4.7 pg/ml) (P = 0.01). Data suggest that increased levels of free T may be a risk factor for prostatic carcinoma. In addition, although no differences in hair patterning were detected between cases and controls within this older population, further research (i.e., prospective trials or case-control studies among younger men) may be necessary to determine if hair patterning serves as a viable biomarker for this disease, especially given the strong association between free T levels and baldness.

This article has been cited by other articles:

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553. [Abstract] [Full Text] [PDF]

				R. S. Legro, A. R. Kunselman, L. Demers, S. C. Wang, R. Bentley-Lewis, and A. Dunaif Elevated Dehydroepiandrosterone Sulfate Levels as the Reproductive Phenotype in the Brothers of Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2134 - 2138. [Abstract] [Full Text] [PDF]

				W. Demark-Wahnefried, J. M. Schildkraut, E. Hawk, B. I. Graubard, and R. A. Breslow Correspondence re: E. Hawk, et al., Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000 Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 415 - 416. [Full Text]

				L. P. Hale, D. T. Price, L. M. Sanchez, W. Demark-Wahnefried, and J. F. Madden Zinc {{alpha}}-2-Glycoprotein Is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer Clin. Cancer Res., April 1, 2001; 7(4): 846 - 853. [Abstract] [Full Text]

				P. G. Cohen, P. A. Lotufo, and J. E. Manson Testosterone and Cardiovascular Risk Factors Arch Intern Med, July 10, 2000; 160(13): 2064 - 2065. [Full Text] [PDF]

				M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]

				E. Hawk, R. A. Breslow, and B. I. Graubard Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 523 - 527. [Abstract] [Full Text]

				W. Demark-Wahnefried, J. M. Schildkraut, D. Thompson, S. M. Lesko, L. McIntyre, P. Schwingl, D. F. Paulson, C. N. Robertson, E. E. Anderson, and P. J. Walther Early Onset Baldness and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 325 - 328. [Abstract] [Full Text]

				P. A. Lotufo, C. U. Chae, U. A. Ajani, C. H. Hennekens, and J. E. Manson Male Pattern Baldness and Coronary Heart Disease: The Physicians' Health Study Arch Intern Med, January 24, 2000; 160(2): 165 - 171. [Abstract] [Full Text] [PDF]

				L. Kopelovich, D. E. Henson, A. F. Gazdar, B. Dunn, S. Srivastava, G. J. Kelloff, and P. Greenwald Surrogate Anatomic/Functional Sites for Evaluating Cancer Risk: An Extension of the Field Effect Clin. Cancer Res., December 1, 1999; 5(12): 3899 - 3905. [Full Text] [PDF]